Skip to content
Est. 1998 proudly celebrating 27 years of standing behind American companies
American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

Cocrystal Pharma, Inc. (COCP)

$0.90 -2.17% NASDAQ: COCP · 15-min delayed
  • BOTHELL, Washington
  • Public · NASDAQ: COCP
  • 10 employees
$13.3MMarket cap
$2.0MRevenue · FY2020
-$8.8MNet income
10Employees
COCPNASDAQ
2008IPO

About Cocrystal Pharma, Inc.

Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). The company has one reportable and operating segment dedicated to the research and development company's novel orally administered antiviral influenza candidate. The company has pipeline products for diseases like : Influenza, Norovirus, Coronavirus, Respiratory Viruses, and Hepatitis C.

This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.

Reported figures

Financial summary

Revenue FY2020
$2.0M
Net income
-$8.8M
Total assets
$9.7M
Market cap
$13.3M

Source: SEC EDGAR · updated Jun 7, 2026

Multi-year

Revenue & profit trend

Revenue Net income
FY 2025

Financial statements

Income statement

Revenue
$0
Operating expenses
$9.0M
Operating income
-$9.0M
Net income
-$8.8M
EPS (basic)
$-0.78
EPS (diluted)
$-0.78

Balance sheet

Total assets
$9.7M
Current assets
$8.1M
Total liabilities
$3.4M
Current liabilities
$2.2M
Shareholders’ equity
$6.3M

Cash flow

Operating cash flow
-$8.2M
Investing cash flow
-$12.0K
Financing cash flow
$8.2M
Net cash flow
$0

Statements via Polygon.io (SEC filings)

NASDAQ: COCP
$0.90 -2.17%

15-minute delayed · data by Polygon.io

Past year · hover for prices

$0.86 $1.94

52-week range

Market cap
$13.3M
EPS (diluted)
$-0.78
Shares outstanding
14.8M
Open
Day range
Prev close
Volume
IPO date
Apr 1, 2008

Cocrystal Pharma, Inc. (COCP) Stock Price

  • Reported a net loss of $8.8M in FY2020.
  • Trading 54% below its 52-week high.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

No reviews yet. Be the first to review Cocrystal Pharma, Inc..

Write a review
Newsroom

News about Cocrystal Pharma, Inc.

News & sentiment via Polygon.io

FAQ

Cocrystal Pharma, Inc.: frequently asked questions

Is Cocrystal Pharma, Inc. an American company?

Cocrystal Pharma, Inc. is a US-based company headquartered in Bothell, Washington, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.

Where is Cocrystal Pharma, Inc. headquartered?

Cocrystal Pharma, Inc. is headquartered in Bothell, Washington, United States.

Is Cocrystal Pharma, Inc. publicly traded?

Yes — Cocrystal Pharma, Inc. is a publicly traded company. Its stock trades under the ticker symbol COCP on the NASDAQ.

What does Cocrystal Pharma, Inc. do?

Cocrystal Pharma, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.

Explore

Similar companies

Browse all →